Patents by Inventor Matthew SEEFELDT

Matthew SEEFELDT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200354400
    Abstract: The invention provides methods and systems for production of recombinant protein, and particularly, for production of recombinant protein from inclusion bodies. For example, in one aspect, the method comprises providing a protein preparation comprising inclusion bodies, preparing an inclusion body dispersion, and exposing the protein preparation to high pressure in a pressure vessel, to disaggregate and refold the inclusion body protein.
    Type: Application
    Filed: April 24, 2020
    Publication date: November 12, 2020
    Inventors: Matthew Seefeldt, Eliana Gomez
  • Publication number: 20190218247
    Abstract: The invention provides methods and systems for production of recombinant protein, and particularly, for production of recombinant protein from inclusion bodies. For example, in one aspect, the method comprises providing a protein preparation comprising inclusion bodies, preparing an inclusion body dispersion, and exposing the protein preparation to high pressure in a pressure vessel, to disaggregate and refold the inclusion body protein.
    Type: Application
    Filed: August 14, 2018
    Publication date: July 18, 2019
    Inventors: Matthew Seefeldt, Eliana Gomez
  • Publication number: 20140302589
    Abstract: The invention provides methods and systems for production of recombinant protein, and particularly, for production of recombinant protein from inclusion bodies. For example, in one aspect, the method comprises providing a protein preparation comprising inclusion bodies, preparing an inclusion body dispersion, and exposing the protein preparation to high pressure in a pressure vessel, to disaggregate and refold the inclusion body protein.
    Type: Application
    Filed: May 30, 2014
    Publication date: October 9, 2014
    Applicant: Barofold, Inc.
    Inventors: Matthew Seefeldt, Eliana Gomez
  • Patent number: 8697848
    Abstract: The present invention provides methods for reducing and/or evaluating the immunogenic potential of a therapeutic protein preparation. The present invention further provides pharmaceutical compositions of therapeutic proteins and methods of treatment with the same, the compositions having low immunogenic potential and/or improved efficacy. The invention achieves these goals by evaluating therapeutic protein preparations for subvisible protein particulates, which can contribute significantly to the overall immunogenic potential of the protein preparation. Further, by maintaining the content of such subvisible protein particulates to below an immunogenic threshold level, the resulting pharmaceutical composition is less likely to result in a loss of tolerance (e.g., upon repeated administration), thereby improving both the safety and efficacy profile of the therapeutic.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: April 15, 2014
    Assignees: The Regents of the University of Colorado, Barofold, Inc.
    Inventors: Matthew Seefeldt, Theodore W. Randolph, Amber Haynes Fradkin, John Carpenter
  • Publication number: 20120070406
    Abstract: The present invention provides methods for reducing and/or evaluating the immunogenic potential of a therapeutic protein preparation. The present invention further provides pharmaceutical compositions of therapeutic proteins and methods of treatment with the same, the compositions having low immunogenic potential and/or improved efficacy. The invention achieves these goals by evaluating therapeutic protein preparations for subvisible protein particulates, which can contribute significantly to the overall immunogenic potential of the protein preparation. Further, by maintaining the content of such subvisible protein particulates to below an immunogenic threshold level, the resulting pharmaceutical composition is less likely to result in a loss of tolerance (e.g., upon repeated administration), thereby improving both the safety and efficacy profile of the therapeutic.
    Type: Application
    Filed: July 19, 2011
    Publication date: March 22, 2012
    Applicants: The Regents of the University of Colorado, A Body Corporate, Barofold, Inc.
    Inventors: Matthew SEEFELDT, Theodore W. RANDOLPH, Amber Haynes FRADKIN, John CARPENTER